close icon

JNJ Stock Preparing for a Bullish Breakout

JNJ stock did not start the year in the best way possible. The share price fell from an all-time high of $148.32 on January 17th to as low as $118.62 on May 29th, erasing 20% of the company’s market capitalization. Such declines come to remind us that even the best of blue chip stocks do not always rise. On the other hand, price drops often provide a great buying opportunity. Is JNJ stock’s plunge a chance to buy the dip or the start of a bigger crash? The chart below looks encouraging.
jnj stock elliott wave analysis
The hourly chart of Johnson & Johnson allows us to put the recent plunge into Elliott Wave perspective. It looks like JNJ stock has drawn a textbook A-B-C simple zigzag correction with an ending diagonal in the position of wave C. It is also interesting to notice that wave B is a smaller simple zigzag, labeled (a)-(b)-(c), where wave (b) is a triangle.

According to the theory, once a correction is over, the larger trend resumes. In JNJ stock’s case, the larger trend is clearly to the upside, so it makes sense to expect more strength from now on towards a new all-time high near $150 per share. The proper way to take advantage of the anticipated recovery is to wait for a decisive breach of the upper line of the ending diagonal and then put a stop-loss order right below the bottom of wave 5 of C at $118.60. As long as this level holds, the positive outlook remains valid. Given that JNJ stock has already slightly breached the 2-4 line of the diagonal, the situation currently provides an excellent risk/reward ratio of 5.6. So to answer the question from the first paragraph, it definitely looks more like a buy-the-dip opportunity than the beginning of a bear market. The bulls are still alive and kicking.

Did you like this analysis? Learn to do it yourself with our Elliott Wave Video Course!



Stay informed with our newsletter

Latest Elliott Wave analysis on different topics delivered to you weekly.

Privacy policy
You may also like:

T Rowe Price Vulnerable After Fibonacci Encounter

Founded in 1937 and based in Baltimore, Maryland, T Rowe Price is one of the largest asset management companies in the world. At the end of Q1 2019 its assets under management stood at $1.11T. That is T for trillion. Besides, T Rowe Price is also a public company which is why it is of…

Read More »

Momo Inc. – The Tinder of China Looks Promising

Based in Beijing, China, Momo Inc. operates a mobile-based social and entertainment platform. The company was founded in 2011 and became public in late-2014. The Tinder of China, as Momo is often referred to, first turned a profit in 2015 and has been enjoying strong earnings and revenue growth in the last three years. Momo…

Read More »

TTD Stock: Don’t Let that 8-fold Surge Seduce You

The Trade Desk Inc. provides a self-service omni-channel software platform enabling clients to purchase and manage data-driven digital advertising campaigns. TTD stock is trading on NASDAQ since September 2016. In less than three years, the shares have surged from the IPO price of $28.75 to over $232 earlier this month. Early investors have managed to…

Read More »

Mondi Group: Little Known Firm, Well Known Pattern

Even Mondi Group themselves acknowledge that not too many people have heard their name. “Our name may not be familiar to the public, but our products are” is written on the second page of the company’s 2018 annual report. Mondi, listed on the London Stock Exchange, is a global paper and packaging company, headquartered in…

Read More »

Swedbank to Benefit from a Bullish Elliott Wave Cycle

It took Swedbank, one of Sweden’s biggest financial institutions, ten years to return to its pre-crisis glory. The stock rose from as low as SEK 14.70 in March 2009 to SEK 234 in February 2017 – less than SEK 2 below its February 2007 peak. And just when it looked like a new all-time high…

Read More »

FOSL Stock Ready to Exceed Expectations?

In October 2013, Fossil Group had a market cap of roughly $7.5 billion. The watchmaker was enjoying record sales and profits, which was supposed to propel FOSL stock, then hovering above $130 a share, even higher. Fast-forward six years and the company is currently valued at less than $650 million with the shares barely above…

Read More »

Bristol-Myers: Elliott Wave Setup can Double the Price

Bristol-Myers Squibb is in the process of acquiring Celgene in a $74 billion dollar cash-and-stock deal including debt. The deal faced opposition from hedge funds Wellington Management and Starboard Value, but ultimately gained shareholder approval on April 12th. Arbitrageurs, who aim to profit from the discrepancy between the market price and the deal closing price,…

Read More »

More analyses